Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS
Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.
Related Articles
Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL
Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.
Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL
Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2…
BGB-16673 Demonstrates Initial Antitumor Activity, Tolerability in Select Relapsed/Refractory B-Cell Malignancies
BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.
A Promising Treatment for High-Risk Non-Muscle Invasive… : Oncology Times
An abstract is unavailable.
Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grants, in Partnership with Pelotonia & AACR
$700,000 over three years for female associate professors performing research that has a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis,…
IMNN-01 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer
After an additional 7 months of follow-up, IMNN-001 plus chemotherapy produced a 13-month increase in median OS in advanced ovarian cancer
UW Medical Center – Montlake Entrance Upgrade and Waterproofing
Learn about the renovation project at UW Medical Center. Discover how facility upgrades are enhancing patient care, modernizing spaces, and improving the healthcare experience.
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial
PURPOSETo assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC).METHODSIn this trial, patients…
Health-related quality of life in 62 patients with diffuse low-grade glioma during a non-therapeutic and progression-free phase: a cross-sectional study
Journal of Neuro-Oncology – Few studies have evaluated the health-related quality of life (HRQoL) of patients with diffuse low-grade glioma (LGG) during a clinical and…
Help Fund an Early-Career Researcher
Eighty-eight cents of every dollar you give does directly to cancer research. Cancer Research Saves Lives.